Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Just now! The results of the second round of national drug procurement were released CStone Pharmaceuticals initiates ...

INR:0738. play microgaming slots R&D Daily: AstraZeneca's PD-L1 inhibitor receives priority review, reducing the number of treatments by half Phase 3 clini ...

INR:0464. denmark vs norway football Wuhan will build a special hospital based on the "Xiaotangshan" model and it will be completed before February 3 " ...

INR:6695. aus world cup squad CStone Pharmaceuticals initiates clinical trial of PD-L1 inhibitor combined with FGFR4 inhibitor Microhotspot丨A ticket scalper ...

INR:8092. fruits kingdom slot free AstraZeneca's PD-L1 inhibitor receives FDA priority review, reducing the number of treatments by half Three generic dr ...

INR:9702. 247 casino Novartis' MET inhibitor receives breakthrough therapy designation, while Roche's PD-L1 inhibitor expands patient population Shanghai Pharmaceutica ...